Skip to main content
Clinical Trials/NL-OMON38270
NL-OMON38270CompletedPhase 2

Effects of Sildenafil on pulmonary artery pressure in patients with heart failure with preserved ejection fraction and pulmonary hypertension - Sildenafil in HFpEF and PH

niversitair Medisch Centrum Groningen0 sites52 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
52

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • PH secondary to HFpEF defined as mean PAP larger 25 mmHg, wedge larger 15, LVEF larger 45
  • NYHA II-IV

Exclusion Criteria

  • other cause of PH
  • severe noncardiac limitation to exercise
  • coronary ischemia or recent myocardial infarction (<6 months)
  • hypotension , RR< 90/50
  • ongoing nitrate therapy
  • significant left sided valve disease
  • severe liver dysfunction
  • unable to read and comprehend Dutch language

Investigators

Similar Trials